目的观察β-catenin/Slug信号特异性抑制剂FH535与EMT的关系,探讨LPCAT1在调节子宫颈癌细胞侵袭、转移和生长中的作用。方法采用sh-NC和sh-LPCAT1转染Hela细胞,利用载体(Vector)组和LPCAT1过表达质粒转染SiHa细胞,将SiHa细胞分为对照组(...目的观察β-catenin/Slug信号特异性抑制剂FH535与EMT的关系,探讨LPCAT1在调节子宫颈癌细胞侵袭、转移和生长中的作用。方法采用sh-NC和sh-LPCAT1转染Hela细胞,利用载体(Vector)组和LPCAT1过表达质粒转染SiHa细胞,将SiHa细胞分为对照组(Con)、LPCAT1组、LPCAT1+FH535组和FH535组。运用CCK-8法和集落形成试验检测子宫颈癌细胞的增殖。通过伤口愈合试验和Transwell实验检测子宫颈癌细胞的转移、侵袭能力。应用Western blot分析细胞中LPCAT1、β-catenin/Slug信号通路和EMT相关蛋白的表达。结果与Vector组相比,LPCAT1组SiHa细胞的活力、集落数、迁移和侵袭细胞数均显著增加(P<0.05);与sh-NC组相比,sh-LPCAT1组Hela细胞的活力、集落数、迁移和侵袭细胞数均显著降低(P<0.05)。与LPCAT1组相比,LPCAT1+FH535组SiHa细胞中Wnt4(1.18±0.05 vs 0.80±0.06)、β-catenin(1.05±0.08 vs 0.77±0.05)、Slug(1.13±0.06 vs 0.28±0.02)、Cyclin D1(0.99±0.06 vs 0.44±0.02)、N-cadherin(0.91±0.07 vs 0.46±0.03)和vimentin(0.95±0.06 vs 0.49±0.03)表达降低(P<0.05),E-cadherin(0.44±0.03 vs 0.58±0.03)表达增加(P<0.05)。此外,与LPCAT1组相比,LPCAT1+FH535组SiHa细胞的集落数(224±15 vs 146±11)、迁移数(85±3 vs 51±4)和侵袭数(166±10 vs 90±5)均降低(P<0.05)。结论LPCAT1表达增加可能通过激活β-catenin/Slug信号通路促进子宫颈癌的转移和进展,LPCAT1的靶向治疗有望提高子宫颈癌患者的预后。展开更多
Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target ...Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin αvβ3 overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics.展开更多
单纯疱疹病毒1型(herpes simplex virus type 1,HSV-1)是一种能够在各类人群中携带和传播并能引起包括口唇疱疹、荚膜炎、角膜炎和病毒性脑炎等疾病的重要病原体。虽然已有多种类型的HSV-1疫苗处于研发的不同阶段,但仍没有商业化的疫苗...单纯疱疹病毒1型(herpes simplex virus type 1,HSV-1)是一种能够在各类人群中携带和传播并能引起包括口唇疱疹、荚膜炎、角膜炎和病毒性脑炎等疾病的重要病原体。虽然已有多种类型的HSV-1疫苗处于研发的不同阶段,但仍没有商业化的疫苗上市销售。临床上使用的特异性抗HSV-1药物如阿昔洛韦、伐昔洛韦和喷昔洛韦等也面临严重的抗药性威胁,开发新的特异性抗HSV-1药物是当前所面临的主要任务之一。siRNA是一种长度为20~25核苷酸的双链RNA,通过在转录后水平上沉默基因表达发挥干扰作用。siRNA作为一种新的、有潜力的抗病毒药物备受关注,发展也较为迅速。综述近年来siRNA在抗HSV-1方面的研究进展,包括靶向HSV-1关键基因和HSV-1互作的宿主细胞基因的siRNA设计、递送和靶向策略。展开更多
文摘目的观察β-catenin/Slug信号特异性抑制剂FH535与EMT的关系,探讨LPCAT1在调节子宫颈癌细胞侵袭、转移和生长中的作用。方法采用sh-NC和sh-LPCAT1转染Hela细胞,利用载体(Vector)组和LPCAT1过表达质粒转染SiHa细胞,将SiHa细胞分为对照组(Con)、LPCAT1组、LPCAT1+FH535组和FH535组。运用CCK-8法和集落形成试验检测子宫颈癌细胞的增殖。通过伤口愈合试验和Transwell实验检测子宫颈癌细胞的转移、侵袭能力。应用Western blot分析细胞中LPCAT1、β-catenin/Slug信号通路和EMT相关蛋白的表达。结果与Vector组相比,LPCAT1组SiHa细胞的活力、集落数、迁移和侵袭细胞数均显著增加(P<0.05);与sh-NC组相比,sh-LPCAT1组Hela细胞的活力、集落数、迁移和侵袭细胞数均显著降低(P<0.05)。与LPCAT1组相比,LPCAT1+FH535组SiHa细胞中Wnt4(1.18±0.05 vs 0.80±0.06)、β-catenin(1.05±0.08 vs 0.77±0.05)、Slug(1.13±0.06 vs 0.28±0.02)、Cyclin D1(0.99±0.06 vs 0.44±0.02)、N-cadherin(0.91±0.07 vs 0.46±0.03)和vimentin(0.95±0.06 vs 0.49±0.03)表达降低(P<0.05),E-cadherin(0.44±0.03 vs 0.58±0.03)表达增加(P<0.05)。此外,与LPCAT1组相比,LPCAT1+FH535组SiHa细胞的集落数(224±15 vs 146±11)、迁移数(85±3 vs 51±4)和侵袭数(166±10 vs 90±5)均降低(P<0.05)。结论LPCAT1表达增加可能通过激活β-catenin/Slug信号通路促进子宫颈癌的转移和进展,LPCAT1的靶向治疗有望提高子宫颈癌患者的预后。
基金supported by Guangdong Basic and Applied Basic Research Foundation(2023A1515010969)Natural Science Foundation of Top Talent of SZTU(GDRC202305).
文摘Anti-tumor angiogenesis therapy, targeting the suppression of blood vessel growth in tumors, presents a potent approach in the battle against cancer. Traditional therapies have primarily concentrated on single-target techniques, with a specific emphasis on targeting the vascular endothelial growth factor, but have not reached ideal therapeutic efficacy. In response to this issue, our study introduced a novel nanoparticle system known as CS-siRNA/PEITC&L-cRGD NPs. These chitosan-based nanoparticles have been recognized for their excellent biocompatibility and ability to deliver genes. To enhance their targeted delivery capability, they were combined with a cyclic RGD peptide (cRGD). Targeted co-delivery of gene and chemotherapeutic agents was achieved through the use of a negatively charged lipid shell and cRGD, which possesses high affinity for integrin αvβ3 overexpressed in tumor cells and neovasculature. In this multifaceted approach, co-delivery of VEGF siRNA and phenethyl isothiocyanate (PEITC) was employed to target both tumor vascular endothelial cells and tumor cells simultaneously. The co-delivery of VEGF siRNA and PEITC could achieve precise silencing of VEGF, inhibit the accumulation of HIF-1α under hypoxic conditions, and induce apoptosis in tumor cells. In summary, we have successfully developed a nanoparticle delivery platform that utilizes a dual mechanism of action of anti-tumor angiogenesis and pro-tumor apoptosis, which provides a robust and potent strategy for the delivery of anti-cancer therapeutics.
文摘单纯疱疹病毒1型(herpes simplex virus type 1,HSV-1)是一种能够在各类人群中携带和传播并能引起包括口唇疱疹、荚膜炎、角膜炎和病毒性脑炎等疾病的重要病原体。虽然已有多种类型的HSV-1疫苗处于研发的不同阶段,但仍没有商业化的疫苗上市销售。临床上使用的特异性抗HSV-1药物如阿昔洛韦、伐昔洛韦和喷昔洛韦等也面临严重的抗药性威胁,开发新的特异性抗HSV-1药物是当前所面临的主要任务之一。siRNA是一种长度为20~25核苷酸的双链RNA,通过在转录后水平上沉默基因表达发挥干扰作用。siRNA作为一种新的、有潜力的抗病毒药物备受关注,发展也较为迅速。综述近年来siRNA在抗HSV-1方面的研究进展,包括靶向HSV-1关键基因和HSV-1互作的宿主细胞基因的siRNA设计、递送和靶向策略。
